Biotechnology

NeoGenomics is raising $275M via convertible notes. We dissect the sophisticated financing, from dilution-hedging calls to the market impact for investors.

A Chinese firm is expanding its role in the hidden, high-stakes supply chain for semiconductors and advanced manufacturing. Here’s why it matters.

Adaptive Biotechnologies plans to separate its profitable diagnostics arm from its high-potential discovery engine. A deep dive into the financial calculus.

Adaptive Biotechnologies' new debt offering is more than a financial tune-up; it's a calculated move to sever a costly royalty deal and arm its star MRD division for a separate future.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

Icelandic biotech Alvotech seeks $125M in a complex dual offering to advance its low-cost drug pipeline, but regulatory hurdles and financial pressures loom.

HPE's new quantum strategy isn't just about qubits; it's about building a resilient bridge between classical HPC and the quantum future.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

Nordicus Partners reveals promising data for gum disease and oral lesions, betting its future on a unique Nordic acquisition strategy and a Nasdaq uplisting.

A new clinical trial, backed by the Michael J. Fox Foundation, tests a radical idea: an oral drug derived from carbon monoxide to fight Parkinson's.

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

New Phase 3 data for Takeda's oveporexton shows it treats the root cause of narcolepsy, not just symptoms. A key FDA decision looms this year.

Tri Delta’s 27-year, $185M partnership with St. Jude is more than charity. It's a masterclass in grassroots economic power fueling life-saving innovation.

A new wave of advanced cancer drugs is set to upend the market. As the EGFR inhibitor space surges towards $16B, we analyze the strategies behind the disruption.

As biopharma navigates a maze of privacy laws and AI, a new platform aims to centralize patient consent, turning a compliance nightmare into a bridge for trust.

A record $10M gift establishes a new research chair, honoring a titan of Canadian finance and positioning Montreal to solve the critical organ shortage.

As AI promises to revolutionize medicine, enterprises face complex challenges. A new ISG study aims to chart the critical partner ecosystem.

As AI drug discovery faces a crucial test, Terray Therapeutics hires a proven dealmaker. Can Lisa Decker translate digital promise into clinical reality?

Big Pharma is pouring over $1 billion into AI to design complex drugs, trading lab guesswork for algorithms. It's a high-stakes play to fix a broken R&D model.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.